Rapid amelioration of hypercholesterolemia by LDL apheresis (LDL-A) was performed for long-standing nephrotic syndrome (NS) with hyperlipidemia due to focal segmental glomerulosclerosis (FGS) and the clinical data and prognosis were compared between LDL-A-treated and nontreated groups. Seventeen steroid-resistant NS patients treated with LDL-A (LDL-A group) and 10 NS patients treated with steroids only (steroid-monotherapy (SM) group) were compared. Serum cholesterol and phospholipid levels were significantly lowered only in the LDL-A group (p < 0.01, respectively). The LDL-A group showed a significant decrease of urinary protein (UP, p < 0.01) and increase of serum albumin (p < 0.05). Average time needed to achieve a decrease of UP to less than nephrotic range (< 3.5 g/day) was significantly shorter in the LDL-A group than in the SM group (p < 0.01). Although this is not a prospective study, it is highly expected that a rapid improvement of hypercholesterolemia by LDL-A in steroid-resistant NS will provide more rapid relief from NS than steroid therapy alone.

Keywords:
Focal segmental glomerulosclerosis, LDL apheresis, Liposorber, Nephrotic syndrome
1.
Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978;10:213–218.
2.
Brown CR, Cameron JS, Turner DR, Chantler C, Ogg CS, Williams DG, Bewick M: Focal segmental glomerulosclerosis with rapid decline in renal function (‘malignant FSGS’). Clin Nephrol 1978;10:51–61.
3.
Moorhead JF, Chan MK, El-Nahas M, et al: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;ii:1309–1311.
4.
Diamond JR, Karnovsky M: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 1988;33:917–924.
5.
D’Amico G, Gentile M, Mansias G, et al: Effect of vegetarian soy diet on hyperlipidemia in nephrotic syndrome. Lancet 1992;339:1131–1134.
6.
Kasiske BL, Velosa J, Halstenson CE, et al: The effects of lovastatin in hyperlipidemic patients with nephrotic syndrome. Am J Kidney Dis 1990;15:8–15.
7.
Gordon BR, Kelsey S, Bilheimer DW, Brown DC, Dau PC, Gotto AM, Illingworth DR, Jones PH, Leitman SF, Prihoda J, Stein EA, Stern TN, Zavotal JH, Zwiener RJ: Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose absorption system. Am J Cardiol 1992;70:1010–1016.
8.
Thompson GR, Miller JP, Breslow JL: Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br Med J 1985;291:1621–1673.
9.
Mabuchi H, Michishita I, Takeda M, Fujita H, Koizumi J, Takeda R, Oonishi M: A new low-density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987;68:19–25.
10.
Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S: Does LDL apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 1994;9:257–264.
11.
Yashiro M, Muso E, Matsushima M, Nagura R, Sawanishi K, Sasayama S: Two-compartment model of cholesterol kinetics for establishment of treatment strategy of LDL apheresis in nephrotic hypercholesterolemia. Blood Purif 1994;12:317–326.
12.
Kojima S, Harada-Shiba M, Toyota Y, Kimura G, Tsushima M, Kuramochi M, Sakata T, Uchida K, Yamamoto A, Omae T: Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992;15:185–190.
13.
Yamamoto A, Kojima S, Harada-Shiba M, et al: Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate cellulose column. Artif Organs 1992;16:177–181.
14.
Banfi G, Colturi C, Montgnino G, Ponticelli C: The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. Transplantation 1990;50:594–596.
15.
Hoyer JR, Venrier R, Najarian JS, Raij L, Simmons RL, Michael AF: Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972;ii:343–348.
16.
Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Jurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP: Effect of plasma protein adsorption on protein excretion in kidney transplant recipient nephrotic syndrome. N Engl J Med 1994;330:7–14.
17.
Yoshizawa N, Kusuma Y, Matsumoto K: Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Nephron 1989;51:370–376.
18.
Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B: A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 1975;23:37–40.
19.
Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996;334:878.
20.
Carrie BJ, Golbetz H, Michaels AS, et al: Creatinine: An inadequate filtration marker in glomerular disease. Am J Med 1980;69:177–182.
21.
Petrichenko I, Daret D, Larrue J, Shakhov Y: Effect of VLDL on the inhibition of arachidonic acid transformation by dexamethasone in cultured smooth muscle cells. Biochim Biophys Acta 1993;24:183–187.
22.
Yokoyama K, Sakai S, Yamaguchi Y, et al: Complete remission of the nephrotic syndrome due to focal glomerular sclerosis achieved with low-density lipoprotein adsorption alone. Nephron 1996;72:318–320.
23.
Velosa JA, Holley KE, Torres VE, Offord KP: Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 1983;58:568–577.
24.
Eddy AA: Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 1989;135:719–733.
25.
Eddy AA: Molecular insights into renal interstitial fibrosis. Am J Soc Nephrol 1996;7:249.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.